LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Quidel Corp

Abrir

14.73 -5.7

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.42

Máximo

15.62

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+97.12% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-248M

961M

Abertura anterior

20.43

Fecho anterior

14.73

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 de mar. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 de mar. de 2026, 23:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard: Confirms Discussions With Brown-Forman

26 de mar. de 2026, 23:29 UTC

Ganhos

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 de mar. de 2026, 23:28 UTC

Ganhos

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 de mar. de 2026, 23:27 UTC

Ganhos

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 de mar. de 2026, 23:08 UTC

Conversa de Mercado

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 de mar. de 2026, 23:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod in Deal Talks With Brown-Forman -- WSJ

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 de mar. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 de mar. de 2026, 22:26 UTC

Ganhos

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 de mar. de 2026, 22:08 UTC

Ganhos

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Global Energy Roundup: Market Talk

26 de mar. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 de mar. de 2026, 22:00 UTC

Ganhos

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

97.12% parte superior

Previsão para 12 meses

Média 30.75 USD  97.12%

Máximo 38 USD

Mínimo 25 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat